Welcome to our dedicated page for CalciMedica news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CalciMedica stock.
CalciMedica, Inc. (Nasdaq: CALC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule drugs for treating autoimmune disorders, organ transplant rejection, and other immune diseases. The company's primary focus is on developing therapies for life-threatening inflammatory diseases with a high unmet need. Utilizing its proprietary technology, CalciMedica targets the inhibition of calcium release-activated calcium (CRAC) channels. This approach is designed to modulate the immune response and protect against tissue cell injury, offering therapeutic benefits for diseases with no approved therapies.
CalciMedica's lead product candidate, Auxora™, is an intravenous-formulated CRAC channel inhibitor that has shown promising results in multiple clinical trials. The company is currently conducting several significant studies:
- CARPO Trial: A Phase 2b international, randomized, double-blind, placebo-controlled, dose-ranging trial aimed at establishing Auxora's efficacy in treating acute pancreatitis with accompanying systemic inflammatory response syndrome (SIRS). The trial has successfully enrolled 216 patients, with topline data expected in the second quarter of 2024.
- CRSPA Study: An investigator-sponsored Phase 1/2 trial focusing on pediatric patients with acute lymphoblastic leukemia (ALL) experiencing asparaginase-induced pancreatic toxicity (AIPT). This study aims to define an optimal pediatric dose for Auxora and is expected to provide additional data by the second half of 2024.
- KOURAGE Trial: A Phase 2 trial targeting patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This randomized, double-blind, placebo-controlled study plans to evaluate 150 patients, with data anticipated in 2025.
CalciMedica has also secured substantial funding through a securities purchase agreement, raising up to $55 million in gross proceeds. This financing will support ongoing and planned clinical trials, bringing the company closer to achieving its goal of providing effective treatments for critically ill patients.
Recent achievements include the presentation of positive Phase 1/2 CRSPA study results at the 65th Annual American Society of Hematology Meeting and the clearance of an Investigational New Drug (IND) application by the FDA for the KOURAGE trial. Additionally, the company has engaged in a private placement financing, ensuring continued financial health and the ability to pursue pivotal clinical trials.
Founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, CalciMedica is headquartered in La Jolla, CA. For more information, visit www.calcimedica.com.
CalciMedica announced positive topline data from its Phase 2b CARPO trial evaluating Auxora™ in treating acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). The trial met its primary objective, showing a statistically significant dose response. Key findings include up to a 43.6% reduction in median time to solid food tolerance, a 61.7% reduction in severe organ failure, and a 100% reduction in hospital stays longer than 21 days. The trial demonstrated Auxora's safety and tolerability, with plans for a Phase 3 trial and an upcoming FDA meeting.
CalciMedica announced it will host a conference call on June 27, 2024, at 8:30 a.m. ET to discuss topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS). The clinical-stage biopharmaceutical company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. Interested parties can join the call via a live webcast or dial-in numbers provided on CalciMedica's investor relations website. A webcast replay will be available post-event.
CalciMedica reported a significant quarter ending March 31, 2024, marked by the completion of enrollment for the Phase 2b CARPO trial for Auxora™ in acute pancreatitis (AP), with topline data expected in 2Q 2024.
Additionally, the KOURAGE Phase 2 trial for severe acute kidney injury (AKI) will start patient enrollment in 2Q 2024, with data expected in 2025. A related abstract will be presented at Digestive Disease Week (DDW) 2024.
Financially, the company completed a $54 million private placement, with $20.4 million received upfront and $33.1 million pending from warrant exercises. With $25.7 million in cash and equivalents, operations are funded into the second half of 2025. Total operating losses were $5.8 million for Q1, offset by a $5.6 million gain from warrant liability adjustment, resulting in a $0.1 million net income.
CalciMedica Inc. announces an upcoming presentation at Digestive Disease Week 2024 where collaborators from Cedars-Sinai will present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis. The presentation will highlight the similarities between the benefits of Auxora and those seen in COVID-19 pneumonia.
FAQ
What is the current stock price of CalciMedica (CALC)?
What is the market cap of CalciMedica (CALC)?
What is CalciMedica, Inc. focused on?
What is Auxora™?
What is the CARPO trial?
What are CRAC channels?
What are the latest updates from CalciMedica?
How is CalciMedica funded?
Where is CalciMedica headquartered?
Are there any approved therapies for the diseases CalciMedica targets?
What is the KOURAGE trial?
Who founded CalciMedica?
